School of Medicine Publications and Presentations
Document Type
Article
Publication Date
3-8-2022
Abstract
Background: Cognitive impairment is a core deficit across psychotic disorders, the causes and therapeutics of which remain unclear. Epidemiological observations have suggested associations between cognitive dysfunction in psychotic disorders and cardiovascular risk factors, but an underlying etiology has not been established.
Methods: Neuropsychological performance using the Brief Assessment of Cognition in Schizophrenia (BACS) was assessed in 616 individuals of European ancestry (403 psychosis, 213 controls). Polygenic risk scores for coronary artery disease (PRSCAD) were quantified for each participant across 13 p-value thresholds (PT 0.5-5e-8). Cardiovascular and psychotropic medications were categorized for association analyses. Each PRSCAD was examined in relation to the BACS and the optimized PT was confirmed with five-fold cross-validation and independent validation. Functional enrichment analyses were used to identify biological mechanisms linked to PRSCAD-cognition associations. Multiple regression analyses examined PRSCAD under the optimal PT and medication burden in relation to the BACS composite and subtest scores.
Results: Higher PRSCAD was associated with lower BACS composite scores (p = 0.001) in the psychosis group, primarily driven by the Verbal Memory subtest (p < 0.001). Genes linked to multiple nervous system related processes and pathways were significantly enriched in PRSCAD. After controlling for PRSCAD, a greater number of cardiovascular medications was also correlated with worse BACS performance in patients with psychotic disorders (p = 0.029).
Conclusions: Higher PRSCAD and taking more cardiovascular medications were both significantly associated with cognitive impairment in psychosis. These findings indicate that cardiovascular factors may increase the risk for cognitive dysfunction and related functional outcomes among individuals with psychotic disorders.
Recommended Citation
Zhang, L., Hill, S. K., Guo, B., Wu, B., Alliey-Rodriguez, N., Eum, S., Lizano, P., Ivleva, E. I., Reilly, J. L., Keefe, R. S. E., Keedy, S. K., Tamminga, C. A., Pearlson, G. D., Clementz, B. A., Keshavan, M. S., Gershon, E. S., Sweeney, J. A., & Bishop, J. R. (2022). Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders. Progress in neuro-psychopharmacology & biological psychiatry, 113, 110464. https://doi.org/10.1016/j.pnpbp.2021.110464
Publication Title
Progress in neuro-psychopharmacology & biological psychiatry
DOI
10.1016/j.pnpbp.2021.110464
Academic Level
faculty
Mentor/PI Department
Neuroscience
Comments
PMC Copyright notice Publisher's Disclaimer